Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965888961> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W1965888961 endingPage "S427" @default.
- W1965888961 startingPage "S427" @default.
- W1965888961 abstract "The ZEISIG study (Ziprasidone Experience in Schizophrenia in Germany/Austria) investigated the effectiveness of ziprasidone as measured by discontinuation rates and mean changes of the BPRS total. Secondary objectives included quality of life, subjective well-being, tolerability, and safety.Two hundred and seventy-six subjects with schizophrenia and schizoaffective disorder were treated within an open-label, 12-week, prospective, flexible-dose observational trial of ziprasidone (40–160 mg/day). Baseline and outcome assessments mainly included Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions Scale (CGI), Short-Form 12 (SF-12), and Subjective Well-being under Neuroleptic treatment (SWN-K).Study discontinuation due to any cause was evident in 58% of subjects, most of them within the first 4 weeks after study initiation. In study completers, ziprasidone was associated with improvements in BPRS total (44.8 to 33.6; p < 0.001), CGI, SF-12, and SWN-K total scores (80.5 to 89.5). Ziprasidone was related to reduction of weight, fasting glucose, and serum lipids. No cardiovascular adverse event or significant increase of the QTc interval was observed.Approximately 60% of subjects discontinued ziprasidone prematurely, probably related to an initial and overall underdose. The present study confirmed previous tolerability and safety data of ziprasidone as well as results of its effectiveness. Independent from reason to switch, previous antipsychotic class, and severity of illness at baseline, the recommended starting dose of 80 mg/day as well as the maximum treatment dose of 160 mg/day may not be sufficient for a selected subgroup of patients." @default.
- W1965888961 created "2016-06-24" @default.
- W1965888961 creator A5004367944 @default.
- W1965888961 creator A5018001165 @default.
- W1965888961 creator A5044970030 @default.
- W1965888961 creator A5082571155 @default.
- W1965888961 creator A5084671689 @default.
- W1965888961 date "2006-01-01" @default.
- W1965888961 modified "2023-09-25" @default.
- W1965888961 title "P.3.c.056 Efficacy of ziprasidone in the treatment of schizoaffective disorder:an analysis of 2 fixed-dose, placebo-controlled trials" @default.
- W1965888961 doi "https://doi.org/10.1016/s0924-977x(06)70543-0" @default.
- W1965888961 hasPublicationYear "2006" @default.
- W1965888961 type Work @default.
- W1965888961 sameAs 1965888961 @default.
- W1965888961 citedByCount "1" @default.
- W1965888961 crossrefType "journal-article" @default.
- W1965888961 hasAuthorship W1965888961A5004367944 @default.
- W1965888961 hasAuthorship W1965888961A5018001165 @default.
- W1965888961 hasAuthorship W1965888961A5044970030 @default.
- W1965888961 hasAuthorship W1965888961A5082571155 @default.
- W1965888961 hasAuthorship W1965888961A5084671689 @default.
- W1965888961 hasConcept C118552586 @default.
- W1965888961 hasConcept C126322002 @default.
- W1965888961 hasConcept C142724271 @default.
- W1965888961 hasConcept C15744967 @default.
- W1965888961 hasConcept C197934379 @default.
- W1965888961 hasConcept C204787440 @default.
- W1965888961 hasConcept C27081682 @default.
- W1965888961 hasConcept C2776412080 @default.
- W1965888961 hasConcept C2777270317 @default.
- W1965888961 hasConcept C2778375690 @default.
- W1965888961 hasConcept C2778528637 @default.
- W1965888961 hasConcept C2778715236 @default.
- W1965888961 hasConcept C2779727114 @default.
- W1965888961 hasConcept C2780325297 @default.
- W1965888961 hasConcept C2780494398 @default.
- W1965888961 hasConcept C71924100 @default.
- W1965888961 hasConceptScore W1965888961C118552586 @default.
- W1965888961 hasConceptScore W1965888961C126322002 @default.
- W1965888961 hasConceptScore W1965888961C142724271 @default.
- W1965888961 hasConceptScore W1965888961C15744967 @default.
- W1965888961 hasConceptScore W1965888961C197934379 @default.
- W1965888961 hasConceptScore W1965888961C204787440 @default.
- W1965888961 hasConceptScore W1965888961C27081682 @default.
- W1965888961 hasConceptScore W1965888961C2776412080 @default.
- W1965888961 hasConceptScore W1965888961C2777270317 @default.
- W1965888961 hasConceptScore W1965888961C2778375690 @default.
- W1965888961 hasConceptScore W1965888961C2778528637 @default.
- W1965888961 hasConceptScore W1965888961C2778715236 @default.
- W1965888961 hasConceptScore W1965888961C2779727114 @default.
- W1965888961 hasConceptScore W1965888961C2780325297 @default.
- W1965888961 hasConceptScore W1965888961C2780494398 @default.
- W1965888961 hasConceptScore W1965888961C71924100 @default.
- W1965888961 hasLocation W19658889611 @default.
- W1965888961 hasOpenAccess W1965888961 @default.
- W1965888961 hasPrimaryLocation W19658889611 @default.
- W1965888961 hasRelatedWork W137885780 @default.
- W1965888961 hasRelatedWork W1964336925 @default.
- W1965888961 hasRelatedWork W2015871706 @default.
- W1965888961 hasRelatedWork W2043771488 @default.
- W1965888961 hasRelatedWork W2110640372 @default.
- W1965888961 hasRelatedWork W2589247936 @default.
- W1965888961 hasRelatedWork W2884850942 @default.
- W1965888961 hasRelatedWork W3023502736 @default.
- W1965888961 hasRelatedWork W4223500234 @default.
- W1965888961 hasRelatedWork W4317934569 @default.
- W1965888961 hasVolume "16" @default.
- W1965888961 isParatext "false" @default.
- W1965888961 isRetracted "false" @default.
- W1965888961 magId "1965888961" @default.
- W1965888961 workType "article" @default.